BRIEF published on 12/11/2025 at 23:05, 5 months 9 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 5 months 9 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 6 months 1 day ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 6 months 1 day ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 6 months 7 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 6 months 7 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 7 months 10 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
PRESS RELEASE published on 10/10/2025 at 15:30, 7 months 10 days ago Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock Xenetic Biosciences, Inc. announces pricing of underwritten stock offering, aiming to raise $4.5 million for immuno-oncology technologies. Canaccord Genuity acts as bookrunner Xenetic Biosciences Stock Offering Immuno-oncology Technologies Canaccord Genuity S-3 Registration Statement
BRIEF published on 08/13/2025 at 14:05, 9 months 7 days ago Xenetic Biosciences Reports Q2 2025 Financial Results Financial Results Xenetic Biosciences Q2 2025 DNase I Development Partnership Expansions
PRESS RELEASE published on 08/13/2025 at 14:00, 9 months 7 days ago Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q2 2025 results, expands partnership with The Scripps Research Institute for DNase I with CAR T-cell therapies and ends quarter with $4.8M cash Financial Results Xenetic Biosciences DNase I The Scripps Research Institute CAR T-cell Therapies
Published on 05/21/2026 at 01:25, 4 hours 1 minute ago Mongolia Growth Group Announces Completion of Arrangement and Changes to the Board and Executive Leadership
Published on 05/20/2026 at 22:40, 6 hours 46 minutes ago Jaguar Health Reports First Quarter 2026 Financials
Published on 05/20/2026 at 22:15, 7 hours 11 minutes ago Fox River Resources Corporation Obtains Interim Order for Plan of Arrangement and Provides Details of Special Meeting
Published on 05/20/2026 at 15:28, 13 hours 58 minutes ago Sarama Resources Announces Private Equity Placement of A$1.5m
Published on 05/20/2026 at 15:01, 14 hours 25 minutes ago Kidoz Inc. Appoints Tarrnie Williams Jr. as Chief Operating Officer
Published on 05/20/2026 at 22:00, 7 hours 26 minutes ago Nebius and Bloom Energy partner to power AI infrastructure build-out
Published on 05/20/2026 at 21:35, 7 hours 51 minutes ago IGEL and Zscaler Release Healthcare Security Blueprints for Distributed Care Delivery
Published on 05/20/2026 at 20:15, 9 hours 11 minutes ago EQS-Adhoc: AT&S Austria Technologie & Systemtechnik AG: AT&S expands capacity for AI substrates
Published on 05/20/2026 at 19:34, 9 hours 52 minutes ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Final Results Announcement
Published on 05/20/2026 at 19:34, 9 hours 52 minutes ago EQS-Adhoc: AT&S Austria Technologie & Systemtechnik AG: AT&S intends to issue a (Hybrid) Convertible Bond and/or a Hybrid Bond; no dividend for the financial year 2025/26
Published on 05/20/2026 at 18:00, 11 hours 26 minutes ago General shareholders meeting of 20 May, 2026
Published on 05/20/2026 at 17:45, 11 hours 41 minutes ago Report on share repurchases from 13 to 19 May 2026
Published on 05/20/2026 at 15:21, 14 hours 5 minutes ago Statement of transactions in own shares from May 11, 2026 to May 15, 2026
Published on 05/20/2026 at 08:30, 20 hours 56 minutes ago BMI Selects Actisure, the market-leading platform from Cegedim Insurance Solutions, to Power Health & Life Administration Across Latin America
Published on 05/20/2026 at 08:30, 20 hours 56 minutes ago EURAZEO ANNOUNCES THE FIRST CLOSE OF ITS PME V FUND AT OVER €1 BILLION, SEEDED WITH TWO INITIAL INVESTMENTS
